التفاصيل البيبلوغرافية
| العنوان: |
RNAi COMPOUND TARGETED TO THROMBOSPONDIN-1 AND APPLICATIONS THEREOF |
| Document Number: |
20110166199 |
| تاريخ النشر: |
July 7, 2011 |
| Appl. No: |
12/985684 |
| Application Filed: |
January 06, 2011 |
| مستخلص: |
The present invention relates to an RNAi compound and an expression plasmid for inhibiting expression of Thrombospondin-1, which comprises a target sequence selected from Thrombospondin-1 gene. The present invention also related to a pharmaceutical composition comprising the RNAi compound and applications thereof. The RNAi compound can reduce the expression of Thrombospondin-1 to activate immune responses. In addition, the present invention also disclosed that an RNAi compound targeted to Thrombospondin-1 gene can delay tumor progression. |
| Inventors: |
Lai, Ming-Derg (Tainan City, TW); Huang, Shih-Shien (Tainan City, TW); Yen, Meng-Chi (Tainan City, TW); Lin, Chi-Chen (Taichung City, TW); Weng, Tzu-Yang (Tainan City, TW) |
| Assignees: |
National Cheng Kung University (Tainan City, TW) |
| Claim: |
1. An RNAi compound for inhibiting expression of Thrombospondin-1, comprising: a target sequence selected from Thrombospondin-1 gene. |
| Claim: |
2. The RNAi compound as claimed in claim 1, wherein the target sequence comprises 20-25 nucleotides, and is selected from an encoding region corresponding to nucleotides 1 to 3516 of Thrombospondin-1 gene. |
| Claim: |
3. The RNAi compound as claimed in claim 1, wherein the target sequence is SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. |
| Claim: |
4. The RNAi compound as claimed in claim 1, further comprising an Her2/neu gene, wherein the Her2/neu gene connects to the target sequence. |
| Claim: |
5. The RNAi compound as claimed in claim 4, wherein the sequence of the Her2/neu gene is SEQ ID NO: 10. |
| Claim: |
6. The RNAi compound as claimed in claim 1, wherein the RNAi compound is an isolated siRNA, or an shRNA expression plasmid for encoding an siRNA. |
| Claim: |
7. The RNAi compound as claimed in claim 6, wherein the shRNA expression plasmid comprises the target sequence, and a reverse complement of the target sequence. |
| Claim: |
8. An expression plasmid for inhibiting expression of Thrombospondin-1, comprising: a target sequence selected from Thrombospondin-1 gene; and a reverse complement of the target sequence, wherein the target sequence encodes an siRNA targeted to Thrombospondin-1 gene. |
| Claim: |
9. The expression plasmid as claimed in claim 8, wherein the target sequence comprises 20-25 nucleotides, and is selected from an encoding region corresponding to nucleotides 1 to 3516 of Thrombospondin-1 gene. |
| Claim: |
10. The expression plasmid as claimed in claim 8, wherein the target sequence is SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. |
| Claim: |
11. The expression plasmid as claimed in claim 8, further comprising an Her2/neu gene, wherein the Her2/neu gene connects to the target sequence. |
| Claim: |
12. The expression plasmid as claimed in claim 11, wherein the sequence of the Her2/neu gene is SEQ ID NO: 10. |
| Claim: |
13. A pharmaceutical composition, comprising: an RNAi compound, which comprises a target sequence selected from Thrombospondin-1 gene; and a pharmaceutically acceptable carrier. |
| Claim: |
14. The pharmaceutical composition as claimed in claim 13, wherein the target sequence comprises 20-25 nucleotides, and is selected from an encoding region corresponding to nucleotides 1 to 3516 of Thrombospondin-1 gene. |
| Claim: |
15. The pharmaceutical composition as claimed in claim 13, wherein the target sequence is SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. |
| Claim: |
16. The pharmaceutical composition as claimed in claim 13, wherein the RNAi compound further comprises an Her2/neu gene, wherein the Her2/neu gene connects to the target sequence. |
| Claim: |
17. The pharmaceutical composition as claimed in claim 16, wherein the sequence of the Her2/neu gene is SEQ ID NO: 10. |
| Claim: |
18. The pharmaceutical composition as claimed in claim 13, wherein the RNAi compound is an isolated siRNA, or an shRNA expression plasmid for encoding an siRNA. |
| Claim: |
19. The pharmaceutical composition as claimed in claim 18, wherein the shRNA expression plasmid comprises the target sequence, and a reverse complement of the target sequence. |
| Claim: |
20. The pharmaceutical composition as claimed in claim 13, wherein the pharmaceutically acceptable carrier is selected from a group consisting of saline, phosphate buffered saline (PBS), and sterile water. |
| Claim: |
21. A method of treating cancer, comprising: administering a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises: an RNAi compound, which comprises a target sequence selected from Thrombospondin-1 gene; and a pharmaceutically acceptable carrier. |
| Claim: |
22. The method as claimed in claim 21, wherein the target sequence comprises 20-25 nucleotides, and is selected from an encoding region corresponding to nucleotides 1 to 3516 of Thrombospondin-1 gene. |
| Claim: |
23. The method as claimed in claim 21, wherein the target sequence is SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. |
| Claim: |
24. The method as claimed in claim 21, wherein the RNAi compound further comprises an Her2/neu gene, wherein the Her2/neu gene connects to the target sequence. |
| Claim: |
25. The method as claimed in claim 24, wherein the sequence of the Her2/neu gene is SEQ ID NO: 10. |
| Claim: |
26. The method as claimed in claim 21, wherein the RNAi compound is an isolated siRNA, or an shRNA expression plasmid for encoding an siRNA. |
| Claim: |
27. The method as claimed in claim 26, wherein the shRNA expression plasmid comprises the target sequence, and a reverse complement of the target sequence. |
| Claim: |
28. The method as claimed in claim 21, wherein the pharmaceutically acceptable carrier is selected from a group consisting of saline, phosphate buffered saline (PBS), and sterile water. |
| Claim: |
29. The method as claimed in claim 21, wherein the pharmaceutical composition is administered through a gene gun or an intramuscular injection. |
| Current U.S. Class: |
514/44/A |
| Current International Class: |
61; 07; 61; 12 |
| رقم الانضمام: |
edspap.20110166199 |
| قاعدة البيانات: |
USPTO Patent Applications |